Crizotinib versus platinum‐based double‐agent chemotherapy as the first line treatment in advanced anaplastic lymphoma kinase‐positive lung adenocarcinoma

BACKGROUND: To explore the efficacy and safety of crizotinib versus platinum‐based double agent chemotherapy as the first‐line treatment in patients with advanced anaplastic lymphoma kinase (ALK)‐positive lung adenocarcinoma. METHOD: We retrospectively analyzed data from 19 patients with advanced AL...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Thorac Cancer
Autors principals: Zhang, Quan, Qin, Na, Wang, Jinghui, Lv, Jialin, Yang, Xinjie, Li, Xi, Nong, Jingying, Zhang, Hui, Zhang, Xinyong, Wu, Yuhua, Zhang, Shucai
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2015
Matèries:
Original Articles
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4718131/
https://ncbi.nlm.nih.gov/pubmed/26816533
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/1759-7714.12264
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars